Latest Pharma Insights
Herbalife Looks To Drive Growth By Making Internal, Vertical Use Of Nutrition Club Strategy
Direct seller notes strategy with Q3 results, including net sales growing 6% to $1.35bn driven primarily on volume. Other priorities are digital platform offering distributors’ best apps and expanding into entrepreneur and consumer segments with Bioniq brand.
HBW Insight - November 4, 2026
Direct seller notes strategy with Q3 results, including net sales growing 6% to $1.35bn driven primarily on volume. Other priorities are digital platform offering distributors’ best apps and expanding into entrepreneur and consumer segments with Bioniq brand.
HBW Insight - November 4, 2026
Chinese First-In-Class Assets Scoop New VC/PE Funding
In October, Burgeon Therapeutics and Groovy Medicine were among the China ventures closing new early funding rounds to finance the clinical development of first-in-class molecules, in atopic dermatitis and oncology, respectively. BioGeometry, Reju and Allygen also had sizable new financings.
Scrip - November 4, 2026
In October, Burgeon Therapeutics and Groovy Medicine were among the China ventures closing new early funding rounds to finance the clinical development of first-in-class molecules, in atopic dermatitis and oncology, respectively. BioGeometry, Reju and Allygen also had sizable new financings.
Scrip - November 4, 2026
UK Campaign Targets Counterfeit Beauty After Tests Find Mercury, Lead
The UK’s Trading Standards office found that four in 10 counterfeit cosmetics products tested positive for potentially harmful substances.
HBW Insight - November 4, 2026
The UK’s Trading Standards office found that four in 10 counterfeit cosmetics products tested positive for potentially harmful substances.
HBW Insight - November 4, 2026
TCT 2026: Abbott’s Amulet 360 Hits 96.3% Complete LAA Closure at One Year in Pivotal VERITAS Study
Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device at TCT 2026. Complete closure was seen in 96.3% of patients, with a 1.8% rate of ischemic stroke or systemic embolism. The device has a CE Mark and FDA approval is expected.
Medtech Insight - November 4, 2026
Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device at TCT 2026. Complete closure was seen in 96.3% of patients, with a 1.8% rate of ischemic stroke or systemic embolism. The device has a CE Mark and FDA approval is expected.
Medtech Insight - November 4, 2026
Amgen Sees Big Sales Growth But Multiple Products Face Threats
Although Amgen’s revenue rose by more than 8% in the third quarter, some blockbusters are losing ground; drug candidates with recent positive late-stage readouts could help fill future gaps.
Scrip - November 4, 2026
Although Amgen’s revenue rose by more than 8% in the third quarter, some blockbusters are losing ground; drug candidates with recent positive late-stage readouts could help fill future gaps.
Scrip - November 4, 2026
Chinese First-In-Class Assets Scoop New VC/PE Funding
In October, Burgeon Therapeutics and Groovy Medicine were among the China ventures closing new early funding rounds to finance the clinical development of first-in-class molecules, in atopic dermatitis and oncology, respectively. BioGeometry, Reju and Allygen also had sizable new financings.
Scrip - November 4, 2026
In October, Burgeon Therapeutics and Groovy Medicine were among the China ventures closing new early funding rounds to finance the clinical development of first-in-class molecules, in atopic dermatitis and oncology, respectively. BioGeometry, Reju and Allygen also had sizable new financings.
Scrip - November 4, 2026
Amgen Sees Big Sales Growth But Multiple Products Face Threats
Although Amgen’s revenue rose by more than 8% in the third quarter, some blockbusters are losing ground; drug candidates with recent positive late-stage readouts could help fill future gaps.
Scrip - November 4, 2026
Although Amgen’s revenue rose by more than 8% in the third quarter, some blockbusters are losing ground; drug candidates with recent positive late-stage readouts could help fill future gaps.
Scrip - November 4, 2026
TCT 2026: Abbott’s Amulet 360 Hits 96.3% Complete LAA Closure at One Year in Pivotal VERITAS Study
Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device at TCT 2026. Complete closure was seen in 96.3% of patients, with a 1.8% rate of ischemic stroke or systemic embolism. The device has a CE Mark and FDA approval is expected.
Medtech Insight - November 4, 2026
Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device at TCT 2026. Complete closure was seen in 96.3% of patients, with a 1.8% rate of ischemic stroke or systemic embolism. The device has a CE Mark and FDA approval is expected.
Medtech Insight - November 4, 2026
Herbalife Looks To Drive Growth By Making Internal, Vertical Use Of Nutrition Club Strategy
Direct seller notes strategy with Q3 results, including net sales growing 6% to $1.35bn driven primarily on volume. Other priorities are digital platform offering distributors’ best apps and expanding into entrepreneur and consumer segments with Bioniq brand.
HBW Insight - November 4, 2026
Direct seller notes strategy with Q3 results, including net sales growing 6% to $1.35bn driven primarily on volume. Other priorities are digital platform offering distributors’ best apps and expanding into entrepreneur and consumer segments with Bioniq brand.
HBW Insight - November 4, 2026
UK Campaign Targets Counterfeit Beauty After Tests Find Mercury, Lead
The UK’s Trading Standards office found that four in 10 counterfeit cosmetics products tested positive for potentially harmful substances.
HBW Insight - November 4, 2026
The UK’s Trading Standards office found that four in 10 counterfeit cosmetics products tested positive for potentially harmful substances.
HBW Insight - November 4, 2026
Hyloris Funds Future Growth With €6m Liquidity Buffer
Hyloris has secured a predominantly non-dilutive €6m financing package, hoping that the financial flexibility will give additional headroom to advance its portfolio and licensing discussions.
Generics Bulletin - November 3, 2026
Hyloris has secured a predominantly non-dilutive €6m financing package, hoping that the financial flexibility will give additional headroom to advance its portfolio and licensing discussions.
Generics Bulletin - November 3, 2026
Samsung Bioepis Ramps Up Profits As It Confirms US Keytruda Biosimilar Filing
As the South Korean biotech company continues to push forward – including by filing a pembrolizumab biosimilar with the US FDA – Samsung Bioepis has reported rising operating profits, already achieving 97% of its 2025 total across the first nine months of the year.
Generics Bulletin - November 3, 2026
As the South Korean biotech company continues to push forward – including by filing a pembrolizumab biosimilar with the US FDA – Samsung Bioepis has reported rising operating profits, already achieving 97% of its 2025 total across the first nine months of the year.
Generics Bulletin - November 3, 2026
NRx Sets Out Ketamine Ambitions After FDA Nod Arrives Early
NRx Pharmaceuticals has set out plans for how it intends to get a foothold in the US ketamine market following FDA approval for its preservative-free IV version. Amid supply shortages, the firm is seeking to benefit from US manufacturing and a unique product presentation.
Generics Bulletin - November 3, 2026
NRx Pharmaceuticals has set out plans for how it intends to get a foothold in the US ketamine market following FDA approval for its preservative-free IV version. Amid supply shortages, the firm is seeking to benefit from US manufacturing and a unique product presentation.
Generics Bulletin - November 3, 2026
Mapping Out Big Pharma’s Obesity Shopping List Beyond The Incretin Rush
With independent late-stage incretin programs thinning, big pharma could look at mechanisms that complement existing weight loss drugs or address their limitations.
In Vivo - November 3, 2026
With independent late-stage incretin programs thinning, big pharma could look at mechanisms that complement existing weight loss drugs or address their limitations.
In Vivo - November 3, 2026
Strategic Intent: How Circio Rebuilt Itself Around Circular RNA
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026